140 related articles for article (PubMed ID: 38897173)
21. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
[TBL] [Abstract][Full Text] [Related]
22. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
23. Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia.
Benito-Vicente A; Uribe KB; Larrea-Sebal A; Palacios L; Cenarro A; Calle X; Galicia-Garcia U; Jebari-Benslaiman S; Sánchez-Hernández RM; Stef M; Lambert G; Civeira F; Martín C
Arterioscler Thromb Vasc Biol; 2022 Jul; 42(7):e203-e216. PubMed ID: 35510551
[TBL] [Abstract][Full Text] [Related]
24. Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
Kumar S; Kang DW; Rezvan A; Jo H
Lab Invest; 2017 Aug; 97(8):935-945. PubMed ID: 28504688
[TBL] [Abstract][Full Text] [Related]
25. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
Lu X
Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
[TBL] [Abstract][Full Text] [Related]
26. Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
Wu Y; Xu MJ; Cao Z; Yang C; Wang J; Wang B; Liu J; Wang Y; Xian X; Zhang F; Liu G; Chen X
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779098
[TBL] [Abstract][Full Text] [Related]
27. A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in db/db mice.
Xu M; Wu X; Liu Z; Ding Y; Kong W; Little PJ; Xu S; Weng J
Biochem Biophys Res Commun; 2022 Sep; 622():163-169. PubMed ID: 35868060
[TBL] [Abstract][Full Text] [Related]
28. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
29. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
[TBL] [Abstract][Full Text] [Related]
30. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
[TBL] [Abstract][Full Text] [Related]
31. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
[TBL] [Abstract][Full Text] [Related]
32. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
[TBL] [Abstract][Full Text] [Related]
33. Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia.
Salaheldin TA; Godugu K; Bharali DJ; Fujioka K; Elshourbagy N; Mousa SA
Nanomedicine; 2022 Feb; 40():102480. PubMed ID: 34748962
[TBL] [Abstract][Full Text] [Related]
34. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
35. A Therapeutic Peptide Vaccine Against PCSK9.
Pan Y; Zhou Y; Wu H; Chen X; Hu X; Zhang H; Zhou Z; Qiu Z; Liao Y
Sci Rep; 2017 Oct; 7(1):12534. PubMed ID: 28970592
[TBL] [Abstract][Full Text] [Related]
36. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
[TBL] [Abstract][Full Text] [Related]
37. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
[TBL] [Abstract][Full Text] [Related]
38. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
[TBL] [Abstract][Full Text] [Related]
39. The LEPIS-HuR-TMOD4 axis regulates hepatic cholesterol homeostasis and accelerates atherosclerosis.
LYu P; Pan H; Hu K; Xue Y; Li Q; Lin R; Zheng S; Guo Z; Guo K
Atherosclerosis; 2024 Jun; 393():117554. PubMed ID: 38663275
[TBL] [Abstract][Full Text] [Related]
40. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
